Entero Healthcare Solutions Ltd
Incorporated in 2018, Entero Healthcare Solutions Limited is a distributor of healthcare products in India[1]
- Market Cap ₹ 5,672 Cr.
- Current Price ₹ 1,304
- High / Low ₹ 1,584 / 970
- Stock P/E 79.4
- Book Value ₹ 387
- Dividend Yield 0.00 %
- ROCE 6.71 %
- ROE 4.98 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Stock is trading at 3.37 times its book value
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Retail Industry: Trading
Part of BSE IPO BSE Allcap BSE Consumer Discretionary Nifty Microcap 250 Nifty Total Market
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|
1,780 | 2,522 | 3,300 | 3,922 | 4,425 | |
1,758 | 2,498 | 3,236 | 3,810 | 4,294 | |
Operating Profit | 22 | 24 | 64 | 112 | 130 |
OPM % | 1% | 1% | 2% | 3% | 3% |
4 | 4 | 6 | 14 | 36 | |
Interest | 20 | 29 | 49 | 66 | 55 |
Depreciation | 16 | 20 | 24 | 25 | 27 |
Profit before tax | -11 | -20 | -4 | 36 | 84 |
Tax % | 42% | 49% | 201% | -12% | |
-15 | -29 | -11 | 40 | 75 | |
EPS in Rs | -1,550.90 | -77.71 | -28.12 | 8.99 | 19.09 |
Dividend Payout % | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 30% |
TTM: | 23% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 66% |
TTM: | 552% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|
Equity Capital | 0.10 | 4 | 4 | 43 | 43 |
Reserves | -32 | -62 | -73 | 1,595 | 1,639 |
720 | 974 | 1,101 | 338 | 361 | |
145 | 210 | 275 | 369 | 609 | |
Total Liabilities | 833 | 1,125 | 1,308 | 2,345 | 2,653 |
189 | 262 | 268 | 289 | 554 | |
CWIP | 2 | 1 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 3 |
643 | 863 | 1,040 | 2,056 | 2,096 | |
Total Assets | 833 | 1,125 | 1,308 | 2,345 | 2,653 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
-69 | -35 | -45 | -37 | |
-31 | -162 | -49 | -704 | |
89 | 211 | 73 | 863 | |
Net Cash Flow | -11 | 14 | -21 | 122 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
Debtor Days | 50 | 54 | 57 | 57 |
Inventory Days | 54 | 49 | 41 | 43 |
Days Payable | 22 | 22 | 25 | 24 |
Cash Conversion Cycle | 82 | 81 | 73 | 77 |
Working Capital Days | 84 | 79 | 72 | 71 |
ROCE % | 1% | 5% | 7% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
1d - Transcript of Q2 FY25 earnings call submitted.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Nov - Extract of Newspaper Advertisements where Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
13 Nov - Audio recording of earnings call uploaded on website.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
13 Nov - Monitoring Agency Report for IPO proceeds utilization.
-
Statement Of Deviation Or Variation For The Quarter Ended September 30, 2024
13 Nov - Statement of deviation in IPO fund utilization.
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptNotesPPT
-
Mar 2024Transcript PPT
Leading Healthcare Product Disributor[1] The company is among the top three healthcare distributors in India in terms of revenue. Further, it achieved the fastest scale-up of operations among healthcare product distributors in India between FY19 - FY22.